KB407’s positive set of results presented at ATS 2026 follows a set of similar positive results that were announced for the ...
Clinical Trials Arena on MSN
Orion Pharma reports Phase I data from TEADES trial for solid tumours
The results showed ODM-212 was well tolerated, with no dose-limiting toxicities and no maximum tolerated dose reached.
Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma June 2, 2026 8:00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results